SEC Form 4 · accession 0000899243-17-009648
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas T. Sheehy
Officer — See Remarks
Period of report
Apr 4, 2017
Accepted (ET)
Apr 6, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Apr 4, 2017 | F | 4,540 | $21.00 | D | 7,460 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award.
Remarks
General Counsel and Corporate Secretary